Arbutus Biopharma Corporation has presented preliminary data from an ongoing Phase IIa trial of RNA interference (RNAi) therapy (AB-729), nucleos(t)ide analogue (NA), and pegylated interferon alfa-2a (IFN) in patients with chronic hepatitis B virus (cHBV) at the European Association for the Study of the Liver (EASL) Congress 2023.
The data from the randomised, open-label, multicentre Phase II trial (NCT04980482) showed a reduction in hepatitis B surface antigen (HBsAg). However, no patient showed sustained loss of circulating HBsAg, which is associated with improved clinical outcomes.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
A total of 43 patients were administered – AB-729 every eight weeks, along with 24 weeks of NA. This was followed by NA and IFN for 12 or 24 weeks in all patients, with the addition of AB-749 in half of the patients.
Of the 41 patients, 38 had HBsAg levels of less than 100IU/ml, indicating a decreased risk of disease deterioration.
The AB-729 monotherapy and combination therapy were well tolerated, although IFN doses were modified in five patients.
Two Phase II trials (NCT04847440 and NCT04820686) for AB-729 combination therapy in patients with cHBV have been terminated thus far.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAccording to GlobalData analysis, the current HBV market is dominated by NA for the long-term treatment of cHBV, with Gilead Science’s Vemlidy (tenofovir alafenamide) being the current market leader. RNAi therapies make up only a small portion of the HBV pipeline, with existing and future players focusing on small molecules (such as NA).
GlobalData is the parent company of Clinical Trials Arena.
